CJC-1295 Long-Term Safety Remains Unknown
Early tests recorded brief unwanted effects. Stage 1 checked early safety; a death stopped the stage 2 trial of possible benefit. CJC-1295 risks from months or years of treatment remain unsettled.
Brief Studies Reported Hot, Red Faces and Headaches
Early CJC-1295 studies and personal reports described several brief unwanted effects. Flushing means your face feels hot and turns red. Other effects included mild headache and red skin at shot sites. Reports also described fluid buildup, brief numbness, tingling, and dizziness [3][15]. Similar effects occur when growth hormone rises for other reasons. Stage 1, the first small human safety tests, found similar brief effects [3][4].
Brief reactions don't settle what months or years of treatment might cause.
In 2006, the Teichman study tested increasing amounts in healthy adults during stage 1. No serious unwanted reactions were reported at the tested amounts [3]. In 2006, Ionescu also reported brief effects without serious events. The amounts were 60 or 90 micrograms for every kilogram the person weighed [4]. Micrograms measure tiny weights; kilograms measure body weight. In 2006, a man suffered a fatal heart attack. The death occurred in a CJC-1295 stage 2 trial of abnormal fat changes. That later trial tested possible benefit and stopped after the death [5].
Excess Growth Hormone Can Make Blood Sugar Harder to Control
The linked CJC-1295 form keeps growth hormone raised between shots. The liver's own hormone involved in growth stays raised too. Other causes of hormone excess raise concerns about lasting increases.
In 2024, a review examined growth hormone, the liver hormone, and insulin. Your blood sugar is controlled partly by the hormone insulin. Insulin also normally slows the release of fat from stored fat. Too much growth hormone can make this control over fat weaker. Fat can then build up where it harms cells. The liver and other body parts may resist insulin. Your body may make extra insulin to compensate [15]. These problems are known in a disease caused by excess growth hormone [15].
The review doesn't establish how much long-term risk CJC-1295 carries.
In 2006, a trial participant in Argentina died after a heart attack. The death stopped the stage 2 trial and company development [5][9]. The investigator suspected heart artery disease that hadn't caused warning symptoms. A fatty deposit inside an artery had torn open. The suspected tear was in the deposit, not the artery. The investigator considered a direct link to the substance unlikely. The company agreed but ended its program [5]. Months or years of human treatment remain untested.

Lasting Safety Findings and Treatment Approval Are Missing
In 2006, Teichman published one stage 1 early safety study. Ionescu published the other study in 2006. Both reported brief effects without serious unwanted reactions at tested amounts [3][4]. Stage 2 tests possible benefit; stage 3 uses larger groups. Neither stage has completed trials showing lasting safety in people. The 2006 stage 2 trial stopped before providing those answers [5][9].
Acceptable findings in small, brief studies aren't proof of lasting safety.
Neither the FDA nor other drug regulators have approved CJC-1295 as treatment [16]. The substance is a drug under study in the United States. FDA's page current as of April 22, 2026 lists withdrawn requests. The requests asked FDA to consider pharmacies mixing CJC-1295 and ipamorelin acetate. The acetate name means the salt form of ipamorelin. FDA kept the safety warnings after withdrawal. Ipamorelin acetate remains in Category 2, FDA's group flagged for safety concerns. This listing concerns businesses making large batches for clinics or pharmacies. The safety listing gives those businesses no permission to prepare the substance. Separate rules cover pharmacies mixing medicine for one patient's prescription. Withdrawal doesn't explain what those pharmacies may do with either substance [16].
Sports rules ban CJC-1295 both during contests and between contests [7].
People Trying the Pair Also Report Hunger and Stomach Trouble
Accounts of CJC-1295 with ipamorelin describe effects from both substances [12]. Animal tests found that ipamorelin prompted growth hormone without greatly raising other hormones [12]. These include cortisol, a stress hormone, and prolactin, which helps milk production. People trying CJC-1295 with ipamorelin outside controlled studies report brief hunger. Ipamorelin acts where the body's hunger hormone acts. Other personal accounts describe mild stomach trouble and red shot sites [12]. A controlled human trial hasn't checked these reports.
The pair doesn't have settled safety findings for human treatment.
No completed stage 2 benefit test or larger stage 3 trial tested the CJC-1295 and ipamorelin pair against placebo in people. Placebo is a comparison treatment without the substances being tested. Reports come from personal accounts and early animal tests. Months or years of treatment aren't covered by these findings. A brief reaction tells you little about the lasting risk.
Adding Other Growth-Hormone Substances May Raise Blood Sugar Risks
Medical reviews warn about CJC-1295 combined with similar substances. The substances sermorelin and tesamorelin also imitate the natural starting hormone for growth hormone release. Combining the substances can further raise growth hormone and the liver hormone. Insulin may become less able to keep blood sugar controlled. Cells may multiply more than the body needs [15]. CJC-1295 with added insulin or muscle-building drugs raises similar concerns [15].
More hormone release doesn't establish greater benefit or acceptable risk.
Reviews discuss one way of raising growth hormone at a time. Blood tests follow growth hormone and the liver hormone. Reviews warn about repeated combinations without those blood checks [15]. These concerns don't establish a safe combination for your care.